Chief Research Officer
William E. Rote, Ph.D. is the Chief Research Officer at Travere Therapeutics, Inc. (TVTX), a position he has held since February 2017. In this role, he oversees discovery and translational research, regulatory affairs, quality assurance, biometrics, and technical operations including chemistry, manufacturing, and controls (CMC).[[1]](https://travere.com/our-company/leadership-and-board/william-rote-ph-d/)[[5]](https://travere.com/our-company/leadership-and-board/) At age 62, Dr. Rote's leadership emphasizes urgency in rare disease innovation, stating, "With rare disease, time is not on your side. We must foster courage. Without sacrificing safety, we must speed up delivery of new therapies."[[1]](https://travere.com/our-company/leadership-and-board/william-rote-ph-d/)[[5]](https://travere.com/our-company/leadership-and-board/)
Prior to Travere, Dr. Rote led clinical development at Ardea Biosciences (a subsidiary of AstraZeneca), managing clinical trial execution, operations, data management, and biostatistics. Before that, he held positions of increasing responsibility at Amylin Pharmaceuticals, culminating as vice president and site head for R&D.[[1]](https://travere.com/our-company/leadership-and-board/william-rote-ph-d/) He earned his Ph.D. in pharmacology and bachelor’s degree in pre-medicine from Pennsylvania State University, followed by postdoctoral training at the University of Michigan.[[1]](https://travere.com/our-company/leadership-and-board/william-rote-ph-d/) Recently, on December 24, 2025, Dr. Rote sold 60,000 shares of TVTX stock under a 10b5-1 plan, exercising options at $20.61 per share, and retains direct ownership of 101,443 shares.[[3]](https://www.investing.com/news/insider-trading-news/travere-therapeutics-tvtx-chief-research-officer-sells-24m-in-stock-93CH-4424850)[[7]](https://www.secform4.com/insider-trading/1438533.htm)
View full insider profile →
